{
  "docId": "019de075-f745-744d-a2c3-62fcecd316e9",
  "docSlug": "352ee416e6a97a9b39e1309fafdab0f3",
  "documentTitle": "Genelux | Investor Presentation Deck | 38 slides",
  "authorId": "genelux",
  "authorName": "Genelux",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 13,
  "pageCount": 38,
  "prevPage": 12,
  "nextPage": 14,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 15,
  "notes": "Data table presents ORR, Duration of Response, CA-125 response, PFS, and OS across patient subgroups.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-f745-744d-a2c3-62fcecd316e9/13",
  "deckHref": "/decks/019de075-f745-744d-a2c3-62fcecd316e9",
  "deckJsonHref": "/decks/019de075-f745-744d-a2c3-62fcecd316e9.json",
  "deckAnchorHref": "/decks/019de075-f745-744d-a2c3-62fcecd316e9#slide-13",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.25,
        "x": 0.04,
        "y": 0.215
      },
      "kind": "callout",
      "text": "Key Clinical Takeaways",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c7cca283-a43d-4641-b8bd-eb833cfc1385",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.48,
        "x": 0.48,
        "y": 0.7
      },
      "kind": "disclaimer",
      "text": "*Baseline for ORR & PFS evaluation is the timepoint immediately prior to starting post-Olvi-Vec carboplatin doublet +/- bevacizumab to allow direct comparison to historical data or patients' own previous line of chemotherapy. **Eligible for evaluation: with at least 1 measurable target lesion at baseline; including 2 patients without post-chemo scan after virotherapy, and therefore are assigned to the 'inevaluable for response' category per RECIST1.1. ^Including 3 unconfirmed; 2 in resistant and 1 in refractory groups",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6d5b416a-7173-43ca-a8fd-f5ece0b0bb06",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.25,
        "x": 0.05,
        "y": 0.3
      },
      "kind": "list",
      "text": "Promising ORR and PFS, and clinical reversal of platinum resistance and refractoriness among patients with PRROC. All patients had documented progressive disease at enrollment. Overall response rate in 27 patients was 54% with 7.6-month median duration of response. Historical PFS in this patient population is ~4 mos",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d1b9bc7c-ca63-4069-b144-40c6946aadcd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.6,
        "x": 0.36,
        "y": 0.275
      },
      "kind": "table",
      "text": "Overall Response Rate (ORR) & Progression-Free Survival (PFS)*",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b0a1a042-0099-4caa-9d75-477248ee8af3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.8,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "Clinically-Meaningful Responses in Heavily Pretreated Patients",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "51804e45-6741-4394-bd66-5e4c02033722",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "db8e05a9-e4aa-4ae5-ac3e-669b215c078b",
      "evidence": "table/data: Overall Response Rate (ORR) & Progression-Free Survival (PFS)*",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 38,
      "from": 10,
      "beatId": "523d1cf4-1cd0-4572-8561-e435ff7a2275",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "Slides 10-38 present Olvi-Vec as a solution, detailing its competitive advantages, clinical results, and market potential.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}